MEDIAN Technologies (Paris:ALMDT) (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions and services provider in a new phase II clinical trial on Non Small Cell Lung Cancer (NSCLC). The trial is sponsored by Oxford Oncology, a global biopharmaceutical company developing anti-cancer therapies and will include clinical sites located in four Asian countries: Japan, China, Korea and Taiwan.
"This project provides further proof of our growing operational strengths in Asia and our commitment to support our customers in this important region," said Fredrik Brag, CEO of MEDIAN Technologies. "We now have a number of ongoing studies in various countries in Asia, and we have a growing installed base of imaging centers using our Lesion Management Solutions (LMS) software for these trials. This is an exciting study and we look forward to developing a long-term partnership with Oxford Oncology," Fredrik Brag added.
MEDIAN will organize the independent central reviews of the images for this study. MEDIAN services will notably include charter drafting, investigator site support, image collection and quality control, image review by radiologists with MEDIAN LMS, a comprehensive suite of software modules for the review of images and quantitative assessment of response to therapy in clinical trials.
Images will be acquired in 50 Asia-based clinical sites, with an anticipated total enrollment of 250 patients.
The total project award is approximately €417,000 (eq. $545,500) for MEDIAN.
AI outperforms doctors in diagnostics but falls short as a clinical assistant